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Since 2006 when we last reviewed the literature concerning the
use of purine analogues in hairy cell leukaemia (HCL), results from
several new and updated series have been published. Here we
examine these reports and consider their implications for patient
management. The two purine analogues pentostatin and cla-
dribine remain the ﬁrst-line treatments of choice for all patients
with HCL. Although they have not been compared in randomised
trials, they appear to be equally effective. A complete response is
important for the long-term outcome and we look at how best this
can be achieved. Evidence is emerging which supports the use of
either purine analogue plus an anti-CD20 monoclonal antibody
after relapse, though questions remain concerning the scheduling
of the monoclonal antibody. Patients refractory to the purine an-
alogues may require alternative agents.
© 2015 The Authors. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The treatment of hairy cell leukaemia (HCL) with purine analogues is one of the greatest successes
in the history of cancer treatment. From 1958, when Bouroncle et al. [1] ﬁrst described the disease,e), claire.dearden@rmh.nhs.uk (C.E. Dearden), daniel.catovsky@icr.ac.uk (D.
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were among the ﬁrst to be given pentostatin (Nipent, Supergen, Dublin, CA, USA) [2e8], or cladribine
(Leustatin, Ortho-Biotech, Bridgewater, NJ, USA) [9e14], are still alive 30 years later. Many are still in
their ﬁrst remission 15 years and more after treatment [15,16]. Long-term survival cannot be taken for
granted, however. It is the result of careful patient management, from ﬁrst-line treatment onwards.
There have been a number of developments of relevance to purine analogue treatment since our last
review of the literature in 2006 [17]. In particular, longer follow-up is available, enabling the long-term
assessment of outcomes after initial pentostatin or cladribine and the evaluation of these agents when
used at second and subsequent lines of therapy [15,18,19]; the combination of a purine analogue with
rituximab (MabThera, Roche Products Ltd, Hertfordshire, UK) has been evaluated for the treatment of
relapsed HCL [20e22]; a number of new agents have become available for non-responders to purine
analogues, or for patients requiring salvage therapy (see the chapters by Kreitmann, Zenz and Forconi
in this issue); cladribine for subcutaneous administration (LITAK, Lipomed Gmbh, Weil am Rhein,
Germany) has been widely introduced [23,24]; there is a move towards improving the long-term
outcome by converting a partial response (PR) to a complete response (CR) [15,25]; and evidence-
based guidelines have recently been published [25e27]. The purpose of this review is to provide an
update of the available literature and of developments in our own large series. In the second sectionwe
discuss the implications of these ﬁndings for the treatment and management of patients receiving a
purine analogue.
Updated results from the published series
First line purine analogue treatment
Responses to ﬁrst-line treatment
Earlier retrospective studies of pentostatin and cladribine reported overall response rates (ORR) of
more than 85% and CR rates of around 75%, with median relapse-free survival (RFS) up to 15 years
(Supplementary Table S1) [28e36]. These results have been conﬁrmed by recent studies, all retro-
spective (Table 1), including long-term data from three earlier series: from the Scripps Clinic [37], from
Bologna [18], and our own series, updated in 2009 [19], and reviewed in 2011 with a focus on the
implications for clinical practice [15]. There are also two series, from Spain and France, with some
minor overlap of patients from previous reports [38,39] and three new reports from Turkey, India and
Mexico [40e42]. Four of these studies report results with both cladribine and pentostatin, while the
other four report only cladribine.
In all eight recent studies the ORR was >95% and the CR rate >75%. Three large series which
included both agents, from France, Spain and the UK, found no difference in ORR or CR rates between
pentostatin and cladribine [19,38,39]. The Italian series included both agents, but did not analyse the
results separately [18]. Rosenberg et al. [37] focused on 88 younger cladribine-treated patients from the
Scripps Clinic, aged 40 years, and reported 100% ORR and 88% CR. In the other three cladribine series
[40e42] the ORR and CR rates were in linewith those from countries with amore established history of
purine analogue treatment. In India, 27 of 35 patients diagnosed with HCL received cladribine, while 8
did not, due to ﬁnancial constraints [41]. In two institutions in Mexico the CR rate with cladribine was
100%; however, only 11/29 patients were able to obtain cladribine and the remainder received inter-
feron [42]. The lack of availability and affordability of cladribine in those countries is a concern.
As in other earlier reported series [13,35], 18 patients treatedwith cladribine in our series (12 at ﬁrst
line and 6 at second line), who remained in PR at the 4e6 month bone marrow (BM) evaluation,
received a repeated cycle 4e7 months after the ﬁrst cycle. This led to a CR in 14 patients (78%) [15].
Similarly, in the Spanish series 8 patients in PR were treated with a second cycle of cladribine, which
led to a CR in 6 patients (75%) [38]. In the Indian series 2 patients received a second cycle of treatment
at 6e8 months and both achieved a CR [41].
Relapse rates
The earlier retrospective studies with 2e5 years median follow-up reported relapses after pen-
tostatin or cladribine in between 10% and 20% [4,12,13], with higher relapse rates in patients who only
Table 1
Outcomes after purine analogue treatment: results from the recently published series.
Study centre Authors & date Purine
analogue
No. eval.
patients
1st line
ORR %
1st line
CR %
Median FU
(months)
Relapsed %
(after CR/PR)
No. eval.
2nd line
patients
2nd line
ORR %
2nd line
CR%
2nd relapse %
(after CR/PR)
% 2nd
malignancies
Scripps Clinic USAa
(pts aged 40 y only)
Rosenberg et al.,
2014 [37]
Cladribine 83 100 88 251 51 (CR)
80 (PR)
27 96 44 e 9 (after)
Bologna, Italye,a Zinzani
et al., 2010 [18]
Pentostatin 10 96 77 105 44 5 88.5 73.5 64 e
Cladribine 75 41
Royal Marsden
Hospital UKa,b
Else et al., 2009 [19] Pentostatin 188 96 82 172 44 26d 97 69c (median RFS 129 m) 1 (before)
12 (after)Cladribine 45 100 76c 108 38 58d
Spain (GELLC)a Lopez
et al., 2014 [38]
Pentostatin 27 100 92 145 51 e e e e e
Cladribine 80 100 88c 63 25 e e e e e
France multicentrea Cornet
et al., 2014 [39]
Pentostatin 99 99 82 58 23 28d e e (median RFS 153 m) 8 (before)
10 (after)Cladribine 281 100 83 53 18 59d e e (median RFS 79 m)
Turkey multicentre Hacioglu et al.,
2015 [40]
Cladribine 78 97 81 28 16 (CR)
23 (PR)
19 100 68 31.5 3 (before)
1 (after)
New Delhi, India Somasundaram
et al., 2014 [41]
Cladribine 27 100 100c 26 18 (CR) 5 100 100c 0 0
Mexico Ruiz-Delgado
et al., 2012 [42]
Cladribine 11 100 100 25 27 (CR) 3 e e e e
Abbreviations: eval. e evaluable; FU e follow-up; CR e complete response; PR e partial response; RFS e relapse-free survival; GELLC e Spanish Cooperative Group on CLL. A dash ()
denotes no information given. ‘Before’ and ‘after’ denote diagnosis of second malignancies before or after purine analogue treatment.
a Includes some results from a previous series, successively followed up with increased recruitment.
b Some analyses were further updated in 2011 [15].
c After a second course of cladribine in some patients.
d Some patients were switched to the alternative purine analogue.
e The results include a further 33 patients treated with interferon and 3 with splenectomy.
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M. Else et al. / Best Practice & Research Clinical Haematology 28 (2015) 217e229220attained a PR compared to those who obtained a CR (Supplementary Table S1). In the earlier studies
with longer follow-up, relapse rates after a CR were 14%e46% with pentostatin, at 5e11 years median
follow-up [7,28,29,32,36] and 27%e37% with cladribine, at 7e10 years median follow-up [31,33e36].
Reported relapse rates after a PR were 21% at 5 years and 73% at 11 years (pentostatin) [32,36] and
50%e100% (cladribine) [31,33,35,36]. Goodman et al. [31] reported a median time to ﬁrst relapse of 44
months after a CR versus 31 months after a PR (p < 0.0005). Two other series also reported longer
median times to ﬁrst relapse in patients in CR (35, 56 months) versus PR (10, 12 months) [32,35].
The recent studies with short median follow-up (2e5 years) reported relapses in 17%e27% (Table 1)
[39e42]. The Turkish study reported a median time to relapse of 36 months after a CR versus 6 months
after a PR [40]. In the recent studies with longer follow-up, relapse rates after pentostatin were 44% at
14 years median follow-up [19] and 51% at 12 years [38]. After cladribine the relapse rates were 25% at 5
years, rising to 54% at 21 years [18,19,37,38]. The Scripps Clinic reported a 51% relapse rate after a CR
versus 80% after a PR, with a median time to relapse of 57 months after a CR and 20 months after a PR
[37].
These results indicate a general pattern of relapses occurring in about half of patients in the long
term, while the rest remain in indeﬁnite remission, suggesting purine analogues may have a curative
potential. Relapses tend to occur in the early years after treatment, with around a quarter of patients in
CR relapsing in the ﬁrst 5 years. Results after a PR are less encouraging, with higher rates of early
relapse and up to 100% relapsing in the longer term. Our study reported a relapse rate of 24% with
pentostatin and 34% with cladribine at 5 years, 42% with both agents at 10 years, and 47%e48%
respectively at 15 years [19], demonstrating a declining proportion of patients relapsing in the later
years. We found that patients still in CR at 5 years had only a 25% risk of relapse by 15 years. Of the 14
patients who achieved a CR after a repeated cycle of cladribine, all but one remained in remission at a
median follow-up of 6 (range 1e16) years [15]. The Spanish study reported that 34% of patients given
pentostatin and 23% given cladribine required further treatment by 5 years and 56% and 40%
respectively by 10 years [38]. The time elapsing between ﬁrst- and second-line treatment was not
signiﬁcantly different between the two agents, but it was longer in patients in CR (median 170months)
versus those in PR (median 44 months; p < 0.001).0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
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Fig. 1. Relapse-free survival (RFS) by response to ﬁrst-line single-agent treatment with either pentostatin or cladribine, showing a
signiﬁcant difference between patients achieving a complete response (CR) versus a partial response (PR). The median RFS was 16
years overall: 20 þ years (not reached) for patients attaining a CR and 4 years after a PR (log-rank p < 0.0001). There was no dif-
ference in RFS by type of treatment (pentostatin or cladribine). Reprinted from: Dearden et al.; Leuk Lymphoma. 2011; 52 Suppl 2:
21e24 [15].
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Median RFS (censored at the latest follow-up date in patients remaining disease-free) was a little
over 13 years in the French series [39] and 16 years in our series [15], with equivalent results for
pentostatin and cladribine in both series. In our series the median RFS for patients in CR was over 20
years (not reached) but only 5 years for those in PR (p < 0.0001; Fig. 1) [15].
Salvage treatment with purine analogues
Outcomes after second and subsequent lines of purine analogue therapy
Several reports have included data concerning the use of purine analogues as salvage therapy,
showing that these agents can still be effective as second- and third-line therapy in a majority of
patients [15,18,31,32,35,37,40]. However, the CR rates tended to be lower at second line (Table 1) and
lower again at third line [15,18,37,40]. The respective rates for the three lines of treatment were: 81%,
66% and 50% in our series [15], 88%, 44% and 20% at the Scripps Clinic [37] and 81%, 68% and 67% in the
Turkish series [40]. Zinzani et al. [18] reported declining CR rates and response duration across 5 lines
of treatment. From 1st line to 5th line respectively, the CR rates were 77%, 73.5%, 70.5%, 65% and 50%.
The median response duration was 2.7, 2.5, 2.2, 1.6 and 1.3 years. Median response duration was also
shorter with each course of treatment in other studies [18,19,31,35,39].
In the French series estimatedmedian RFS after second-line treatment was signiﬁcantly longer with
pentostatin than cladribine (153 versus 79 months; log-rank p ¼ 0.02; hazard ratio: 0.39; 95% conﬁ-
dence interval [CI]: 0.18e0.85) [39]. In our study a second-line CR (versus a PR) was the only factor
signiﬁcantly associated with longer second-line RFS (p < 0.0001). We found that RFS was shorter after
each line of treatment, decreasing from 16, to 11, to 6.5 years, but the decrease was only seen in partial
responders. Importantly, CRs, although progressively less readily attained, were equally durable,
whether obtained with ﬁrst, second or third-line therapy [19].
In the French series, no signiﬁcant differences were observed in second-line CR rates or RFS be-
tween patients who received the same purine analogue again versus those who switched to the
alternative [39]. Similarly, in our series the CR rate was 71% in patients retreated with the same agent
and 68% in those who switched [36].
Outcomes after salvage with chemo-immunotherapy
After relapse, purine analogues combined with the anti-CD20monoclonal antibody rituximab show
good results [20e22,43]. CD20 expression is signiﬁcantly higher in HCL than in other B-cell leukaemias
[44] and rituximab, used as a single agent in HCL, has shown improved response rates by reducing the
degree of BM inﬁltration. However, there is currently a lack of data from randomised trials to evaluate
the efﬁcacy of the combination relative to a purine analogue alone. Results with chemo-
immunotherapy are described in full by Ravandi in this issue, but we include here a further analysis
of our own series, last reported in 2011 [20] and now with increased follow-up and recruitment.
Twenty-six patients who relapsed after a median of 3 (range 1e6) previous lines of purine analogue
therapy were treated with either pentostatin (n ¼ 15) or cladribine (n ¼ 11) combined with rituximab.
Eighteen patients (69%) had already received the chosen purine analogue at one or more previous lines
of therapy. Patients received between 4 and 8 (median 6.5) intravenous infusions of rituximab at
375 mg/m2, concurrently with the purine analogue in 20 patients and sequentially in 6, starting 1e2
months after the completion of purine analogue therapy. Twenty-ﬁve patients were evaluable for
response with an overall response rate of 96% and a CR rate of 88%. There was one PR and one patient
had a good response without conﬁrmation of CR. The only non-responder was successfully treated
with vemurafenib and remained in remission 2½ years later. The patient in PR relapsed after 10months
and died two years later, after 3 further lines of treatment, with anti-CD25 and anti-CD22 antibodies,
and ﬂudarabine with cyclophosphamide. One patient in CR relapsed after 56 months and received
vemurafenib, remaining in PR two years later. Both patients who relapsed had received only 4 infusions
of rituximab.
At a median follow-up of 78 (range 3e136) months from the start of combination treatment, we
compared the RFS of these 26 patients with their own ﬁrst-line RFS after pentostatin or cladribine
alone, using the KaplaneMeier method. Patients remaining in remission were censored at 31st March
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Fig. 2. Relapse-free survival (RFS) following treatment with the combination of a purine analogue plus rituximab compared with the
RFS of these same 26 patients following their earlier ﬁrst-line therapy with a purine analogue (cladribine or pentostatin) alone (log-
rank p < 0.0001).
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signiﬁcantly longer after combination treatment than after ﬁrst-line treatment (hazard ratio: 0.10; 95%
CI: 0.03e0.32; log-rank p < 0.0001; Fig. 2). After combination treatment, RFS at both 5 and 10 years was
87% (95% CI: 72%e100%), versus 35% (16%e53%) at 5 years and 12% (0%e24%) at 10 years after the same
patients' ﬁrst-line treatment. These results, in patients many of whom had multiple previous relapses,
contrast markedly with the declining RFS seen after sequential lines of treatment in patients receiving
a purine analogue alone, as reviewed above.
Caution is needed in interpreting these results. It is possible that, in some patients, the BMmay have
been more heavily inﬁltrated at the start of ﬁrst-line treatment than at the time of combination
therapy. Also, 8/26 of our combination-treated patients had not previously received the particular
purine analogue used in the combination and it is possible that switching to the alternative agent may
in itself have led to an improved outcome, due to a lack of cross-resistance between pentostatin and
cladribine [45]. Lack of cross-resistance is conﬁrmed by another of our other patients (not in the
rituximab-combination series) who was refractory to pentostatin but remains in remission 22 years
after receiving cladribine as a single-agent. On the other hand, 9/26 combination-treated patients
previously had only a partial response and/or a short remission (<2 years) after an earlier line of
treatment using the same purine analogue as was given in the combination, showing clear evidence for
the added beneﬁt of the rituximab component.Second malignancies
The rate of second malignancies observed in the published series varied from 0% at two years
median follow-up [41] (Table 1) to 23% at 9 years median follow-up [31] (Supplementary Table S1). In
our series 31/233 patients (13%) developed known second malignancies (28 after treatment for HCL),
excluding non-melanoma skin cancers. This was equivalent to the age/sex-matched incidence of
cancers in the general population (expected n ¼ 33) [19]. Four of these malignancies were leukaemias/
lymphomas and two were myeloproliferative disorders. In the Scripps Clinic study of younger patients
with very long follow-up (median 21 years) no excess incidence of malignancies was seen [37]. On the
other hand, Cornet et al. [39] reported an excess incidence, with a standardized incidence ratio of 1.86
(95% CI: 1.34e2.51), increasing to 5.32 (95% CI: 2.90e8.92) for second haematological malignancies.
There was no signiﬁcant difference between pentostatin and cladribine. Cornet et al. [39] reviewed the
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studies from population-based registries. They cited several reports of an increased risk, particularly of
second haematological malignancies and concluded that the increased risk is more likely to be related
to the disease itself than the treatment. Intrinsic immune alterations in HCL could provide a mecha-
nism for additional malignancies through diminished anti-tumour defence [39].
Deaths and overall survival
Therewere 45 deaths in our series (19%), equivalent to the age/sex-matched general population rate
(expected n ¼ 57, not signiﬁcant) [19]. Overall survival 15 years after ﬁrst treatment was 78%. Only 8
deaths (3%) were directly related to HCL, following refractory disease [19]. Death rates in other series
were similar. Zinzani et al. reported 15 deaths (12.5%); 5 deaths (4%) were due to refractory HCL [18]. In
the Mexican series 10-year OS was 91% [42]. In the Scripps clinic series of younger patients there were
13 deaths (16%), with a standardizedmortality (observed-to-expected) ratio of 1.85 (95% C.I. 1.07e3.18),
representing a small increase in the risk of death (p ¼ 0.04) [37]. Although the causes of death were
various, 10/13 patients had a documented relapse of HCL before death. KaplaneMeier curves show that
OS 15 years after the ﬁrst course of cladribine was better for complete responders (95%) than for partial
responders (50%; log-rank p ¼ 0.0008) [37].
In the Turkish series there were 8 deaths (8.5%) and survival 5 years after cladribine treatment was
96% [40]. However 4 of these patients had variant HCL and died due to progressive disease. The
remaining 4 patients died due to sepsis before chemotherapy, aspergillus infection during therapy,
development of acute myeloid leukaemia and acute myocardial infarction, respectively. Cornet et al.
[39] reported 11 deaths (2%) directly related to HCL (disease evolution: n ¼ 4; infectious complications
secondary to treatment: n ¼ 7), with similar OS 10-years after pentostatin (86%) and cladribine (93%).
As these latter two series show, treatment-relatedmortality remains an issue, in spite of improvements
in infection management and prophylactic care.
Prognostic factors
Several studies have examined whether there are factors which predict CR, relapse, RFS or OS after
purine analogue treatment. In our earlier review [17] we showed several baseline clinical features
which were identiﬁed as signiﬁcant prognostic factors in individual series using either pentostatin or
cladribine, but with little consensus [8,13,14,28,30e32]. These included anaemia, thrombocytopenia,
adenopathy, splenomegaly, leukocytosis and older age. More recently, leukocytosis was found to
predict a worse response in the Turkish study, though this may have been due to the inclusion of 5
patients (5%) with HCL-variant [40].
In our series, no variable was found to predict a CR [36] and, with very long-term follow-up, factors
predicting OS become increasingly difﬁcult to identify, as deaths in older age from other causes
increasingly confound the analysis. Themost signiﬁcant predictor of longer RFS inmultivariate analysis
was attainment of a CR [19]. In addition, the median RFS for patients with low hemoglobin (<10 g/dL)
and/or low platelets (<100  109/L) was 9 years versus 20 þ years (not reached) for all others
(p < 0.0001). A CR was the only factor signiﬁcantly associated with longer second or subsequent RFS
[19].
Baseline tissue samples for assessing the prognostic signiﬁcance of molecular markers are not
available from long-term series, but later studies have identiﬁed unmutated IGHV genes, VH4e34 usage
and TP53 genemutation as factors adversely affecting response to cladribine, often in associationwith a
bulky spleen and leukocytosis [46,47].
There has been some discussion about whether the prognosis for patients in CR can be further
reﬁned by whether or not minimal residual disease (MRD) is present. Sigal et al. [16] identiﬁed 19
patients from the Scripps Clinic who were in continued CR at a median of 16 years from cladribine
treatment, of whom 47% (9/19) were MRD-negative, 37% (7/19) MRD-positive and 16% with
morphologic evidence of HCL. Thus patients with MRD and even gross morphologic disease can live
many years without relapsing. Lopez et al. [38] found that the median time elapsing between ﬁrst and
second-line treatments was 97 (38e156) months in MRD-positive patients (n¼ 40) versus not reached
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persistence of MRD after therapy with purine analogues is predictive of eventual disease recurrence.Treatment guidelines and patient management
First line purine analogue treatment
Informed by these results from the published series, the purine analogues, pentostatin and cla-
dribine, are still the ﬁrst-line treatments of choice today, as conﬁrmed by recent guidelines [25e27].
The choice of purine analogue and treatment schedule
Pentostatin and cladribine have similar efﬁcacy. First-line ORR, CR rates, relapse rates and RFS were
not signiﬁcantly different between the two agents in our own and other studies, though none of these
studies provided a randomised comparison [19,38,39]. Thus the choice between pentostatin and cla-
dribine as ﬁrst-line treatment is a matter of availability, convenience and cost.
Treatment schedules for pentostatin and cladribine are available in the guidelines [25e27]. Pen-
tostatin is given at 4 mg/m2 every 2 weeks until maximum response, plus one or two extra injections.
With cladribine, subcutaneous delivery may be the most convenient option and appears to have equal
efﬁcacy with the intravenous form [23,24]. We have switched from a 7-day continuous intravenous
infusion of cladribine 0.1 mg/kg/day to subcutaneous cladribine at a dose of 0.14 mg/kg daily for 5 days
[15]. This has advantages for patients in terms of convenience, safety (no intravenous line), and side
effect proﬁle (no infusion-related reactions), and for the healthcare system in terms of capacity and
cost, without any evidence of a negative impact on outcome.
Supportive care
Infections and treatment-related mortality remain a threat and appropriate prophylaxis and
infection management, as described in the guidelines, is imperative [25e27].
The importance of assessing response
There is compelling evidence from the published series that patients who only achieve a PR in
response to purine analogue treatment: are more likely to relapse than thosewho achieve a CR (Table 1
& Supplementary Table S1) [4,12,15,31e33,37,40]; relapse earlier than patients in CR [31,32,35,37,40];
and hence have shorter RFS (Fig. 1) [15]. There is also evidence of shorter OS after a PR than after a CR in
younger patients [37]. Further, it is likely that patients who fail to obtain a CR may have impaired
quality of life, due to cycles of returning disease and retreatment.
The assessment of disease clearance from the BM after completing treatment is therefore an
important endpoint of the initial treatment and should be the standard of care [15,25e27]. For this
assessment a good-quality BM trephine biopsy with immunohistochemistry is the gold standard.
However, evidence is emerging that alternatives more acceptable to patients, such as 8-colour ﬂow
cytometry using peripheral blood or a BM aspirate, may in future be used instead of a trephine biopsy
without loss of accuracy [48]. With pentostatin this assessment should be performed after 8 to 10
cycles of treatment when the full blood count has returned to normal (though lymphopenia will
persist) [25e27]. Following cladribine therapy there is often a delay in clearance of BM disease and
assessment at 4e6 months after the end of treatment is recommended [25e27].
Converting a partial to a complete response
If the assessment shows evidence of remaining disease, further treatment to establish a CR is
recommended [15,18,25,26]. Due care should be given to avoid toxicity and deeper immunosuppres-
sion. The addition of 6e8 doses of rituximab, delivered either concurrently or shortly after the purine
analogue, may help to achieve this goal [25].With pentostatin, if a CR has not been attained after 10e12
injections, further pentostatin alone may not be effective [19], in which case the addition of rituximab
may be considered [25]. With cladribine, we give a repeated cycle 4e6 months after the ﬁrst cycle [15]
and one may consider adding rituximab to the second cycle of cladribine [25].
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recovering health. There is a need to discuss with the patient the relative merits of further immediate
treatment to establish a CR, with the likelihood of a much extended remission, versus freedom from
any further current intervention, but with the prospect of an earlier return of the disease and a poorer
long-term outlook.Long term patient management
With improved management, in our HCL series which now has over 300 patients, only 3 patients
have died in the past 15 years of causes directly related to HCL. Thus, long-term survival is now truly
long-term, with most patients having a normal life expectancy [19].
Follow-up
Patients should be followed closely during treatment and for several months after completion of
therapy, with special attention to appropriate surveillance and treatment for infections resulting from
myelosuppression [49].
For patients who fail to respond to purine analogue treatment, or who relapse within a fewmonths,
tests to conﬁrm the diagnosis of HCL should be performed, to exclude other similar disorders such as
HCL-variant [26].
Patients who remain in PR may require close monitoring, but for those in CR follow-up once or
twice yearly may be sufﬁcient after the ﬁrst year, with a view to identifying any HCL-related health
issues. There does not appear to be a plateau in this disease and relapses may occur even after 20
years [37].
Salvage treatment with chemo-immunotherapy
As with ﬁrst-line therapy, the aim of salvage treatment is to achieve a CR, in order to secure a long-
term second remission and minimise patients' vulnerability to yet further relapses. We have shown
that a CR after a second-line or third-line purine analogue may be as durable as a ﬁrst-line CR [19].
However, although single-agent purine analogues continue to be effective as salvage therapy, with
each successive line of treatment the likelihood of achieving a CR diminishes [15,18,30,31,33,35,37,40]
and RFS becomes shorter [15,18,39]. In contrast, the combination of a purine analogue with rituximab
has proven efﬁcacy as salvage treatment, with minimal toxicity and a high CR rate [20e22,43]. The
guidelines therefore suggest this combination for patients who have relapsed [25,27]. The choice of
purine analoguewill depend on the duration of ﬁrst remission: if short, i.e. <2 years, use the alternative
agent; if longer (>2 years) retreat using the same agent [25,27].
In updating our own series, above, we have shown that this combination can lead to long re-
missions, even in multiply-relapsed patients. Due to the relapses seen in two of our patients who
received only 4 doses, we recommend that 6e8 doses should be given.
Treating refractory disease
Another role for an anti-CD20 monoclonal antibody such as rituximab is to treat patients who
are refractory to cladribine or pentostatin [25,27]. However, although the combination of ritux-
imab with the alternative purine analogue may be effective in non-responders, data are currently
lacking.
Newer agents are available for patients who do not respond to, or relapse after chemo-
immunotherapy, such as the BRAF inhibitors vemurafenib and dabrafenib, the MEK inhibitor trame-
tinib and recombinant immunotoxins such as moxetumomab pasudotox, which binds to CD22. These
agents are explored in the chapters by Zenz and Kreitmann in this issue.Predicting outcomes after purine analogue therapy
In this rare disease, data are still sparse regarding prognostic factors and their implications for
treatment. International collaborations led by the Hairy Cell Leukemia Foundation may begin to
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ﬁrst-line treatment.
At relapse, the presence of aggressive disease, shown by failure to achieve a ﬁrst-line CR, early
relapse (<24 months), unmutated IGHV genes, TP53 gene mutation, VH4e34 use, BM failure, leuko-
cytosis and bulky disease, may indicate the need to consider alternatives to chemo-immunotherapy,
such as immunotoxins or BRAF and MEK inhibitors [26].
Failure to achieve a CR has been shown to predict a poorer long-term outcome in many of the series
reported above. MRD positivity is also a predictor of shorter time to relapse in some patients [16,38],
but there is insufﬁcient evidence to suggest that patients in CR should be re-treated until MRD
negativity is reached, except as part of a clinical trial [25].Summary
The purine analogues pentostatin and cladribine remain the ﬁrst-line treatment of choice in HCL,
offering an excellent long-term outlook for patients. Both purine analogues are equally effective and
the choice can be made on the basis of cost, convenience and patient or physician preference.
Guidelines are available concerning treatment schedule, prophylaxis and the management of
infections.
The attainment of a CR is important for long-term relapse-free survival. It is therefore essential that,
after 8e10 courses of pentostatin, or 4e6months after cladribine treatment, an assessment of response
should be made, either by BM biopsy (the gold standard) or by ﬂow cytometry. Patients still in PR may
then be given further treatment with the same purine analogue, with or without rituximab. Studies are
needed to determine the best treatment schedule to convert a PR to a CR.
At relapse, chemo-immunotherapy (pentostatin or cladribine with the addition of rituximab)
shows documented evidence of efﬁcacy, with a high CR rate and long remissions. Studies are needed
to determine the optimum regimen for the rituximab component, but we recommend 6e8 doses,
given either concurrently with the purine analogue or sequentially. For patients failing to respond to
purine analogues, or for those relapsing again after chemo-immunotherapy, newer therapies are
available.
The majority of patients with HCL can now expect a normal lifespan, due to the effectiveness of the
purine analogues, improved management of infections and the ability to salvage patients with chemo-
immunotherapy after relapse. The achievement of a CR is critical to this success and should be the goal
of therapy at each stage.Practice points
 With the aim of establishing long-term relapse-free survival, it is important to attain a com-
plete response to treatment.
 An assessment of response by bone marrow biopsy, or equivalent, is therefore an integral
part of the treatment schedule, following 8e10 courses of pentostatin, or 4e6 months after
cladribine treatment.
 If a complete response has not been attained, further treatment with the same agent is rec-
ommended, unless contraindicated. Evidence in this setting is limited, but it may be bene-
ficial to add 6e8 doses of rituximab.
 Though evidence is again limited, chemo-immunotherapy may also be used for non-
responders to single-agent purine analogue therapy, switching to the alternative purine
analogue.
 Combination chemo-immunotherapy (pentostatin or cladribine with the addition of ritux-
imab) has proven efficacy as a salvage treatment.
 For non-responders, or those who relapse after chemo-immunotherapy, newer agents such
as BRAF inhibitors or immunotoxins are available.
Research agenda
 There have been few randomised trials in HCL. It is to be hoped that the collaborative
research being initiated by the HCL Foundation and others will lead to more such trials.
 It is not known whether patients with poor prognosis would benefit from the addition of an
anti-CD20 monoclonal antibody, such as rituximab, to their first-line purine analogue.
 Research is needed to establish how best to convert a partial response to a complete
response after a standard course of first-line pentostatin or cladribine.
 The optimum regimen for the rituximab component of combination chemo-immunotherapy
needs to be established: the number of doses, the frequency and whether rituximab should
be given concurrently with the purine analogue or sequentially.
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